ArticleCancer medicine2025
Polygenic Risk Score as a Predictor of Bone Fracture or Osteoporosis in Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe association between single nucleotide polymorphisms (SNPs) and fracture risk has been established in various studies. Androgen-deprivation therapy (ADT) for prostate cancer, while extending survival, increases the risk of osteoporosis and bone fracture. This study aimed to assess the predictive value of polygenic risk scores (PRSs) on bone events among prostate cancer patients undergoing ADT.
methodsWe enrolled 24,778 male participants, including 903 prostate cancer patients treated at Taichung Veterans General Hospital. These patients were divided into ADT and non-ADT groups. Nine PRSs related to bone mineral density from the PGS Catalog were tested and categorized into quartiles. Cox proportional hazards regression analysis was performed to evaluate the risk of bone fracture and osteoporosis between groups by PRS quartiles.
resultsAmong the PRSs, PGS002632, PGS002681, and PGS001955 demonstrated the highest areas under the curve (AUCs) for predicting bone events. For PGS002632, the risk was significantly higher in the first quartile (Q1) compared to the fourth quartile (Q4) for patients receiving ADT (HR = 5.934, p = 0.0013), after adjusting for age and comorbidities. Furthermore, within the subgroup of prostate cancer patients in Q1 of PGS002632, the risk was higher for those receiving ADT compared to those not receiving ADT (HR = 3.698, p = 0.0093). Similar results were observed for PGS002681 and PGS001955.
conclusionThis hospital-based cohort study among Han Chinese highlights PRS as a potential biomarker for bone fracture and osteoporosis risk in prostate cancer patients initiating ADT. It provides a basis for personalized risk assessment and early intervention with bone protective strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.